|
|
| (19 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | {{pnc}} | | {{pnc}} |
| − | | + | {{ft|D}} |
| − | ''which risk factors make covid worse/better/no effect'' | + | ''which risk factors / underlying conditions make covid worse/better/no effect;'' |
| | | | |
| | '''[[RSP - identifying risk factors]]''' | | '''[[RSP - identifying risk factors]]''' |
| Zeile 28: |
Zeile 28: |
| | '''[[RSP - Pulmonary disease]]''' | | '''[[RSP - Pulmonary disease]]''' |
| | | | |
| − | '''[[RSP - Cystic fibrosis]]]''' | + | '''[[RSP - Cystic fibrosis]]''' |
| | | | |
| | '''[[RSP - Cardiovascular disease]]''' | | '''[[RSP - Cardiovascular disease]]''' |
| Zeile 39: |
Zeile 39: |
| | | | |
| | '''[[RSP - HIV]]''' | | '''[[RSP - HIV]]''' |
| | + | |
| | + | '''[[Children_with_covid19_disease|RSP - DIS Children]]''' |
| | | | |
| | '''[[RSP - DIS Elderly]]''' | | '''[[RSP - DIS Elderly]]''' |
| Zeile 45: |
Zeile 47: |
| | | | |
| | '''[[RSP - DIS Race]]''' | | '''[[RSP - DIS Race]]''' |
| − |
| |
| − | ''' identifying factors '''
| |
| − | '''Frailty'''
| |
| − |
| |
| − |
| |
| − |
| |
| − | '''Heart'''
| |
| − | {{tp|p=32331955|t=ä. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis |pdf=|usr=}}
| |
| − | {{tp|p=32326691|t=2020. Ticagrelor Can Be an Important Agent in the Treatment of Severe COVID-19 Patients with Myocardial Infarction |pdf=|usr=}}
| |
| − | {{tp|p=32277299|t=2020. Perspective: cardiovascular disease and the Covid-19 pandemic |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32335068|t=ä. Unexpected BP Sensitivity to Angiotensin II in a Patient With Coronavirus Disease 2019, ARDS, and Septic Shock |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | '''Cancer'''
| |
| − | {{tp|p=32278878|t=ä. French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32345594|t=2020. Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study during the COVID-19 Outbreak |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | '''HIV'''
| |
| − | {{tp|p=32266501|t=ä. Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − | '''other pharmacology'''
| |
| − |
| |
| − | *[https://www.boston25news.com/news/health/high-blood-pressure-drugs-cleared-covid/UC5LTCKKKVDETBWKJDZ2P776XY/ ACEI/AT1RA not risky ?]
| |
| − | *[https://theconversation.com/we-found-and-tested-47-old-drugs-that-might-treat-the-coronavirus-results-show-promising-leads-and-a-whole-new-way-to-fight-covid-19-136789 dextrometorphan (antitussive compd)]
| |
| − |
| |
| − |
| |
| − | '''Drug abuse'''
| |
| − | {{tp|p=32266501|t=ä. Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − | '''modifiable - tobacco'''
| |
| − | {{tp|p=32303807|t=ä. Electronic cigarette and vaping should be discouraged during the new coronavirus SARS-CoV-2 pandemic |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | '''indoor livin ppl'''
| |
| − | *[https://justthenews.com/politics-policy/coronavirus/doctors-find-hydroxychloroquin-success-rate-91-urge-arizona-maybe-make no sunlight no vitamin d]
| |
| − |
| |
| − | '''Psychiatry'''
| |
| − | {{tp|p=32294689|t=2020. Schizophrenia and COVID-19: risks and recommendations |pdf=|usr=}}
| |
| − | ----
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32334081|t=ä. HEALTH STATUS OF LIVER TRANSPLANTED PATIENTS DURING THE CORONAVIRUS OUTBREAK IN ITALY: A LARGE SINGLE CENTER EXPERIENCE FROM MILAN |pdf=|usr=}}
| |
| − | {{tp|p=32276139|t=2020. COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster |pdf=|usr=}}
| |
| − | {{tp|p=32276140|t=2020. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32270178|t=ä. Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV |pdf=|usr=}}
| |
| − | {{tp|p=32353114|t=ä. Throat Wash Testing and COVID-19 Disease: Should We Put Our Money Where Our Mouth Is?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32161990|t=ä. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China |pdf=|usr=}}
| |
| − | {{tp|p=32328736|t=ä. No adequate evidence indicating hypertension as an independent risk factor for COVID-19 severity |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32357998|t=2020. Cardiac considerations in patients with COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32350632|t=2020. Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32300516|t=ä. Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32283499|t=2020. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32228738|t=ä. Mortality Rate of Infection With COVID-19 in Korea From the Perspective of Underlying Disease |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32256706|t=2020. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32322805|t=ä. SARS-CoV-2 pandemic expanding in sub-Saharan Africa: Considerations for COVID-19 in people living with HIV |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32134381|t=2020. Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32305831|t=ä. Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32232395|t=ä. Initial COVID-19 affecting cardiac patients in China |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32344292|t=2020. COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32296994|t=ä. The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments |pdf=|usr=}}
| |
| − | {{tp|p=C7141546|t=ä. Is low sodium intake a risk factor for severe and fatal COVID-19 infection?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32269089|t=2020. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32341104|t=2020. Cardiovascular comorbidity and its impact on patients with Covid-19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32222253|t=2020. COVID-19: lessons from the Italian reproductive medical experience |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32323577|t=ä. What the oncologist needs to know about COVID-19 infection in cancer patients |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32244059|t=ä. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes |pdf=|usr=}}
| |
| − | {{tp|p=32302703|t=ä. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment |pdf=|usr=}}
| |
| − | {{tp|p=32292696|t=ä. COVID-19 Infection Unmasking Brugada Syndrome |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32325028|t=ä. G6PD deficiency in COVID-19 pandemic: ?a ghost in the ghost? |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32307025|t=ä. Could COVID-19 represent a negative prognostic factor in patients with stroke?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32335339|t=ä. Case Report: One Case of Coronavirus Desease 2019(COVID-19) in Patient Co-nfected by HIV With a Low CD4+ T Cell Count |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32355869|t=ä. The Dermatologist?s Perspective: Why is COVID-19 mortality lower in females than males?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32297089|t=ä. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32224277|t=2020. COVID-19 and immunomodulator/immunosuppressant use in dermatology |pdf=|usr=}}
| |
| − | {{tp|p=32199889|t=2020. Should biologics for psoriasis be interrupted in the era of COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32283234|t=ä. Biologics for psoriasis during COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32246966|t=ä. COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: A word of caution |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32283235|t=ä. Various forms of skin rash in COVID-19 : a reply |pdf=|usr=}}
| |
| − | {{tp|p=32283233|t=ä. Reply to ?COVID-19 can present with a rash and be mistaken for Dengue?: Petechial rash in a patient with COVID-19 infection |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32347144|t=2020. Current perspectives on Coronavirus 2019 (COVID-19) and cardiovascular disease: A white paper by the JAHA editors |pdf=|usr=}}
| |
| − | {{tp|p=32253068|t=2020. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32360995|t=ä. No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease |pdf=|usr=}}
| |
| − | {{tp|p=32278005|t=ä. Non-alcoholic fatty liver diseases in patients with COVID-19: A etrospective study |pdf=|usr=}}
| |
| − | {{tp|p=32348791|t=ä. Clinical characteristics of COVID-19 patients with abnormal liver tests |pdf=|usr=}}
| |
| − | {{tp|p=32348790|t=ä. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis |pdf=|usr=}}
| |
| − | {{tp|p=32305291|t=ä. Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32147409|t=ä. Are children less susceptible to COVID-19?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32335513|t=2020. Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis |pdf=|usr=}}
| |
| − | {{ttp|p=32335512|t=2020. Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32334645|t=2020. Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32171057|t=2020. Implications of COVID-19 for patients with pre-existing digestive diseases |pdf=|usr=}}
| |
| − | {{tp|p=32304642|t=ä. COVID-19 in patients with HIV: clinical case series |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32224304|t=2020. COVID-19 infection in children |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32332856|t=ä. COVID-19 in persons with haematological cancers |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32344304|t=ä. May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications ?|pdf=|usr=}}
| |
| − | {{tp|p=32339776|t=2020. Covid-19, TMPRSS2, and whether android regulation affects pandemic virus gender incidence and age distribution of disease |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32333196|t=2020. Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32320740|t=ä. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32271728|t=2020. Coronavirus Disease 2019 in Children - United States, February 12?April 2, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32345328|t=2020. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32218613|t=ä. Coronaviruserkrankung bei Kindern ? erste Daten aus Wuhan |pdf=|usr=}}
| |
| − | {{ttp|p=32317808|t=ä. COVID-19 bei hospitalisierten Kindern und Jugendlichen: Ein systematischer Review zu publizierten Fallserien (Stand 31 03 2020) und erste Daten aus Deutschland |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32187458|t=ä. SARS-CoV-2 Infection in Children |pdf=|usr=}}
| |
| − | {{tp|p=32163697|t=2020. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32265531|t=ä. COVID-19 and cancer: what we know so far |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32283004|t=ä. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery |pdf=|usr=}}
| |
| − | {{tp|p=32346676|t=ä. Crowdsourcing a crisis response for COVID-19 in oncology |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32284613|t=ä. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32303856|t=ä. Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32270359|t=ä. Acute stroke management pathway during Coronavirus-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32270358|t=ä. No lockdown for neurological diseases during COVID19 pandemic infection |pdf=|usr=}}
| |
| − | {{tp|p=32364125|t=ä. Consulta de epilepsia durante la pandemia de Covid-19: papel de la telemedicina y efectos del confinamiento en pacientes epil�pticos |pdf=|usr=}}
| |
| − | {{tp|p=32364122|t=ä. Neuroinfecciones en tiempos de COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32346676|t=ä. Crowdsourcing a crisis response for COVID-19 in oncology |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32284613|t=ä. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32302077|t=ä. Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32265531|t=ä. COVID-19 and cancer: what we know so far |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32284613|t=ä. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32372803|t=2020. Children and covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32243722|t=2020. Lessons unfolding from pediatric cases of COVID?19 disease caused by SARS?CoV?2 infection |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32231171|t=2020. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32289171|t=ä. Cardiac drugs and outcome in COVID-19: Reply |pdf=|usr=}}
| |
| − | {{tp|p=32289168|t=ä. Cardiac drugs and outcome in COVID - 19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32228252|t=2020. COVID-19, ACE2, and the cardiovascular consequences |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32212348|t=2020. Why is COVID-19 so mild in children?|pdf=|usr=}}
| |
| − | {{tp|p=32339307|t=2020. Additional hypotheses about why COVID-19 is milder in children than adults |pdf=|usr=}}
| |
| − | {{tp|p=32279351|t=2020. We urgently need guidelines for managing COVID-19 in children with comorbidities |pdf=|usr=}}
| |
| − | {{tp|p=32310898|t=2020. Infection of severe acute respiratory syndrome coronavirus 2 in a patient with acquired immunodeficiency syndrome |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32311145|t=2020. SARS-CoV-2 infection in beta thalassemia: Preliminary data from the Italian experience |pdf=|usr=}}
| |
| − | {{tp|p=32243621|t=2020. COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient |pdf=|usr=}}
| |
| − | {{tp|p=32267016|t=2020. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19) |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32339251|t=2020. The importance of hypertension as a risk factor for severe illness and mortality in COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32243894|t=2020. COVID-19 infection in cancer patients: early observations and unanswered questions |pdf=|usr=}}
| |
| − | {{tp|p=32224151|t=2020. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32245656|t=2020. COVID-19 in patients with cardiovascular diseases |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32379903|t=2020. Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32369615|t=2020. Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression |pdf=|usr=}}
| |
| − | {{tp|p=32369606|t=2020. COVID-19 Infection and Sickle Cell Disease: A UK Centre Experience |pdf=|usr=}}
| |
| − | {{tp|p=32314798|t=2020. COVID-19 infection in patients with sickle cell disease |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32312714|t=2020. COVID-19 More Frequent, Severe in Cancer Patients |pdf=|usr=}}
| |
| − | {{tp|p=32352633|t=2020. Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients |pdf=|usr=}}
| |
| − | {{tp|p=32339025|t=2020. Why Fibrinolytic Therapy for STEMI in The COVID-19 Pandemic is Not Your New Best Friend |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32320270|t=2020. Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32345646|t=2020. BTK inhibitors in cancer patients with COVID19: "The winner will be the one who controls that chaos" (Napoleon Bonaparte) |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32259878|t=ä. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID?19: Will cases of psoriasis increase after COVID?19 pandemic?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32376408|t=ä. Clinical Characteristics and Outcomes of COVID-19 Among Patients with Pre-Existing Liver Disease in United States: A Multi-Center Research Network Study |pdf=|usr=}}
| |
| − | {{tp|p=32369240|t=2020. Cutaneous manifestations of a 21st century worldwide fungal epidemic possibly complicating the COVID-19 pandemic to jointly menace mankind |pdf=|usr=}}
| |
| − | {{tp|p=32367558|t=2020. Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32329083|t=2020. (ang.)COVID-19 transmission through host cell directed network of GPCR |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32239590|t=ä. Clinical findings in a patient with haemophilia A affected by COVID?19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32380214|t=ä. Clinical considerations for managing dermatology patients on systemic immunosuppressive and/or biologic therapy during COVID-19 pandemic |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32310015|t=2020. Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32376098|t=ä. A MULTINATIONAL REPORT TO CHARACTERISE SARS-CoV-2 INFECTION IN PEOPLE WITH CYSTIC FIBROSIS |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32220066|t=ä. SARS?CoV?2 and HIV |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32160316|t=ä. Co?infection of SARS?CoV?2 and HIV in a patient in Wuhan city, China |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32347975|t=2020. HIV/SARS-CoV-2 co-infected patients in Istanbul, Turkey |pdf=|usr=}}
| |
| − | {{tp|p=32343410|t=2020. COVID-19 in Tuberculosis patients: a report of three cases |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32293709|t=2020. Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better |pdf=|usr=}}
| |
| − | {{tp|p=32285949|t=2020. Computed Tomography Imaging of an HIV-infected Patient with Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32243919|t=2020. A Rapid Fatal Evolution of Coronavirus Disease-19 in a Patient With Advanced Lung Cancer With a Long-Time Response to Nivolumab |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32251539|t=2020. COVID-19 and liver disease |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32329563|t=2020. Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32347572|t=2020. Outcome of Parkinson s Disease Patients Affected by COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32324968|t=2020. Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2?|pdf=|usr=}}
| |
| − | {{tp|p=32286926|t=2020. Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in Coronavirus-19 (COVID-19) infections and deaths?|pdf=|usr=}}
| |
| − | {{tp|p=32319118|t=2020. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32345686|t=2020. Vulnerable Youth and the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32317311|t=2020. Mitigating the Impacts of the COVID-19 Pandemic Response on At-Risk Children |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32348046|t=2020. Rhumatologie et COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32348045|t=2020. Maladies autoimmunes dans le contexte de la pandemie COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32348044|t=2020. L'hematologie au temps du COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32348042|t=2020. Infection a SARS-CoV-2 et transplantation d'organes solides |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=C7187739|t=ä. Potential Impact of SARS-CoV-2 Infection in HIV-positive Patients in South Africa |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32387456|t=ä. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532) |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32387167|t=ä. The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32376969|t=ä. COVID-19 outcomes in patients with hematologic disease |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32381262|t=ä. Patients with arterial hypertension and COVID-19 are at higher risk of ICU admission |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32402515|t=ä. Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis |pdf=|usr=}}
| |
| − | {{tp|p=32413819|t=2020. Vitamin D concentrations and COVID-19 infection in UK Biobank |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32388171|t=2020. SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome |pdf=|usr=}}
| |
| − | {{tp|p=32291196|t=2020. Is low sodium intake a risk factor for severe and fatal COVID-19 infection?|pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32389521|t=2020. COVID-19 infection in patients following hepato-pancreatico-biliary intervention: An early experience |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32376408|t=ä. Clinical Characteristics and Outcomes of COVID-19 Among Patients with Pre-Existing Liver Disease in United States: A Multi-Center Research Network Study |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32376043|t=ä. Gynecological malignancies with asymptomatic SARS-CoV-2 infection during the convalescence of outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32380288|t=ä. Genetic susceptibility for COVID-19?associated sudden cardiac death in African Americans |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32376098|t=ä. A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32371279|t=ä. Therapeutic Strategy for Patients with Coronavirus Disease 2019 During Left Ventricular Assist Device Supports |pdf=|usr=}}
| |
| − | {{tp|p=32305569|t=2020. Novel Coronavirus Disease 2019 in a Patient on Durable Left Ventricular Assist Device Support |pdf=|usr=}}
| |
| − | {{tp|p=32408961|t=ä. Clinical course of patients infected with severe acute respiratory syndrome coronavirus 2 soon after thoracoscopic lung surgery |pdf=|usr=}}
| |
| − | {{tp|p=32292915|t=ä. Severe COVID-19 With ARDS in a Patient on Durable LVAD Support |pdf=|usr=}}
| |
| − | {{tp|p=32388230|t=2020. Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia |pdf=|usr=}}
| |
| − | {{tp|p=32389426|t=2020. A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: ...|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32360210|t=2020. Letter to the Editor: Fasting plasma glucose associated with mortality rate in T2DM patients with COVID-19 infection |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32387757|t=2020. Is the oncologic patient more susceptible to covid19 but perhaps less likely to undergo severe infection-related complications due to fewer cytokines storm as a consequent of the associated immunodeficiency?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32389584|t=ä. Coronavirus disease 2019 (COVID-19) and cardiovascular risk: A meta-analysis |pdf=|usr=}}
| |
